Innovating Works

RadioClick

Financiado
A versatile ultrafast Click platform for antibody based radio diagnostics
Diagnosing cancer as early as possible is one of the most powerful strategies in modern medicine to improve human well-being. Antibodies (Abs) are excellent molecules that can be used to target specific tumors. As Abs require hour... Diagnosing cancer as early as possible is one of the most powerful strategies in modern medicine to improve human well-being. Antibodies (Abs) are excellent molecules that can be used to target specific tumors. As Abs require hours to days for accumulating on tumor surfaces, the use of Abs for nuclear imaging (such as PET imaging) is limited by the short half-lives of popular radioisotopes. Therefore, we plan to move the step of radiolabeling from the bench to the tumor itself. However, the entanglement of Abs with an artificial chemical probe is one of the most promising but at the same time one of the most technically challenging developmental areas in biotechnology. Our unique approach is based on the production of hybrid-Abs, which combine in only one click step the power of synthetic chemistry with the best of biology (custom-biologics). Our unique selling points are ultra-fast, exceptional bioorthogonal and specific labeling reactions in living organism as well as a both-sided modularity of the connection between Abs and chemical probe. By doing so, high contrast visualization of the cancer will become possible. ver más
30/11/2019
150K€
Duración del proyecto: 18 meses Fecha Inicio: 2018-05-15
Fecha Fin: 2019-11-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-11-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2017-PoC: ERC-Proof of Concept
Cerrada hace 7 años
Presupuesto El presupuesto total del proyecto asciende a 150K€
Líder del proyecto
JOHANNES GUTENBERGUNIVERSITAT MAINZ No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5